^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Kardorisso (asandeutertinib)
i
Other names: TY-9591, TY 9591
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
TYK Medicines
Drug class:
EGFR inhibitor
Related drugs:
10ms
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study. (PubMed, J Thorac Oncol)
TY-9591 demonstrated a favorable safety profile and substantial efficacy in treating EGFR-mutated NSCLC, especially in patients with L858R mutations.
P1 data • PK/PD data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Tagrisso (osimertinib) • Kardorisso (asandeutertinib)
11ms
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects (clinicaltrials.gov)
P1, N=48, Completed, TYK Medicines, Inc | Recruiting --> Completed | Trial completion date: Aug 2024 --> Dec 2024
Trial completion • Trial completion date
|
itraconazole • Kardorisso (asandeutertinib) • rifampicin
11ms
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects (clinicaltrials.gov)
P1, N=6, Completed, TYK Medicines, Inc | Recruiting --> Completed | N=10 --> 6
Trial completion • Enrollment change
|
Kardorisso (asandeutertinib)
11ms
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (clinicaltrials.gov)
P2, N=29, Completed, TYK Medicines, Inc | Active, not recruiting --> Completed | N=60 --> 29
Trial completion • Enrollment change
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Kardorisso (asandeutertinib)
11ms
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects (clinicaltrials.gov)
P1, N=48, Completed, TYK Medicines, Inc | Recruiting --> Completed | Trial completion date: Aug 2024 --> Dec 2024
Trial completion • Trial completion date
|
itraconazole • Kardorisso (asandeutertinib) • rifampicin
11ms
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects (clinicaltrials.gov)
P1, N=6, Completed, TYK Medicines, Inc | Recruiting --> Completed | N=10 --> 6
Trial completion • Enrollment change
|
Kardorisso (asandeutertinib)
1year
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC (clinicaltrials.gov)
P2, N=60, Not yet recruiting, TYK Medicines, Inc
New P2 trial • Metastases
|
cisplatin • carboplatin • pemetrexed • Kardorisso (asandeutertinib)
almost2years
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects (clinicaltrials.gov)
P1, N=48, Recruiting, TYK Medicines, Inc
New P1 trial
|
itraconazole • Kardorisso (asandeutertinib) • rifampicin
almost2years
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (clinicaltrials.gov)
P2, N=60, Active, not recruiting, TYK Medicines, Inc | Recruiting --> Active, not recruiting
Enrollment closed
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Kardorisso (asandeutertinib)
2years
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation (clinicaltrials.gov)
P1, N=105, Completed, TYK Medicines, Inc | Recruiting --> Completed
Trial completion • Metastases
|
EGFR mutation • EGFR exon 19 deletion • EGFR T790M
|
Kardorisso (asandeutertinib)
2years
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects (clinicaltrials.gov)
P1, N=10, Recruiting, TYK Medicines, Inc | Not yet recruiting --> Recruiting
Enrollment open
|
Kardorisso (asandeutertinib)
Share via
